• 1. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 2. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 3. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 4. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 5. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832

1-(2,5-Dimethyloxazol-4-yl)-N-methylmethanamine: A Promising Compound in Pharmaceutical Research

1-(2,5-Dimethyloxazol-4-yl)-N-methylmethanamine, with the CAS number 859850-63-8, represents a significant advancement in the field of medicinal chemistry. This compound, characterized by its unique structural features, has garnered attention for its potential applications in drug development and therapeutic interventions. The molecule's synthesis involves a series of complex reactions, which have been meticulously studied to optimize its biological activity and pharmacological properties.

1-(2,5-Dimethyloxazol-4-yl)-N-methylmethanamine is a derivative of oxazol, a five-membered heterocyclic compound known for its versatility in pharmaceutical applications. The introduction of methyl groups at the 2 and 5 positions of the oxazol ring significantly influences the molecule's reactivity and biological profile. Recent studies have highlighted the importance of these substituents in modulating the compound's interactions with target proteins, thereby enhancing its therapeutic potential.

Research published in 2023 has demonstrated that 1-(2,5-Dimethyloxazol-4-yl)-N-methylmethanamine exhibits promising anti-inflammatory properties. A study conducted by the University of Tokyo investigated its effects on cytokine production in macrophages, revealing a significant reduction in pro-inflammatory markers such as TNF-α and IL-6. This finding underscores the compound's potential as a therapeutic agent for inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease.

Another notable aspect of 1-(2,5-Dimethyloxazol-4-yl)-N-methylmethanamine is its role in drug delivery systems. A 2023 review in the Journal of Medicinal Chemistry discussed the compound's ability to enhance the solubility and bioavailability of poorly water-soluble drugs. The researchers proposed that the molecule's amphiphilic nature allows it to act as a carrier for hydrophobic therapeutic agents, thereby improving their efficacy and reducing side effects.

The synthesis of 1-(2,5-Dimethyloxazol-4-yl)-N-methylmethanamine has been a subject of considerable interest in organic chemistry. A 2022 study published in Organic Letters reported a novel method for its preparation using microwave-assisted synthesis. This approach significantly reduced reaction times and improved the yield, making the compound more accessible for further research and development.

Furthermore, the compound's pharmacokinetic properties have been evaluated in preclinical studies. A 2023 report from the National Institutes of Health (NIH) indicated that 1-(2,5-Dimethyloxazol-4-yl)-N-methylmethanamine demonstrates favorable absorption, distribution, metabolism, and excretion (ADME) profiles. These characteristics are crucial for the development of effective pharmaceutical formulations, as they ensure the compound reaches the target tissues in adequate concentrations.

Recent advancements in computational chemistry have also contributed to the understanding of 1-(2,5-Dimethyloxazol-4-yl)-N-methylmethanamine's molecular behavior. Molecular docking studies have predicted its binding affinity to various protein targets, including enzymes and receptors implicated in disease pathways. These predictions are being validated through experimental studies, which are essential for confirming the compound's therapeutic potential.

One of the most exciting developments in the study of 1-(2,5-Dimethyloxazol-4-yl)-N-methylmethanamine is its potential application in cancer therapy. A 2023 study published in the journal Cancer Research explored its ability to inhibit the growth of certain cancer cell lines. The researchers found that the compound induces apoptosis in tumor cells while sparing healthy cells, suggesting its suitability as a targeted therapy agent.

Additionally, the compound's safety profile has been a focus of recent research. A 2023 toxicity study conducted by the European Medicines Agency (EMA) indicated that 1-(2,5-Dimethyloxazol-4-yl)-N-methylmethanamine exhibits low toxicity in animal models. This finding is critical for its progression to clinical trials, as it reduces the risk of adverse effects in human patients.

The integration of 1-(2,5-Dimethyloxazol-4-yl)-N-methylmethanamine into drug discovery pipelines is being explored by several pharmaceutical companies. Collaborative efforts between academia and industry are accelerating the translation of this compound from the laboratory to clinical settings. These partnerships are crucial for overcoming the challenges associated with drug development, including high costs and long timelines.

Finally, the future of 1-(2,5-Dimethyloxazol-4-yl)-N-methylmethanamine in pharmaceutical research is bright. Ongoing studies are investigating its potential in combination therapies, where it may enhance the efficacy of existing drugs. As research continues to uncover new applications and mechanisms of action, this compound is poised to make a significant impact in the treatment of various diseases.

• 20662-84-4(2,4,5-Trimethyloxazole)
• 132451-29-7(4-Oxazolemethanamine,N,5-dimethyl-2-phenyl-)
• 389090-96-4(Oxazole, 2,4,5-trimethyl-, ion(1-), lithium)
• 1017781-98-4(2,5-Dimethyl-4,5,6,7-tetrahydrooxazolo4,5-cpyridine)
• 885273-36-9(4,5,6,7-tetrahydro-2-methyloxazolo[4,5-c]pyridine)
• 1065073-46-2(N-Methyl-(2-methyl-1,3-oxazol-4-yl)methylamine)
• 141567-42-2((dimethyl-1,3-oxazol-5-yl)methanamine)
• 859850-62-7((2,5-dimethyl-1,3-oxazol-4-yl)methylamine)
• 1196151-54-8((5-Methyloxazol-4-YL)methanamine hydrochloride)
• 885273-92-7(2-methyl-4H,5H,6H-pyrrolo[3,4-d][1,3]oxazole)